Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Informed Consent Process Execution – V 2.0

Posted on By

BA-BE Studies: SOP for Informed Consent Process Execution – V 2.0

Standard Operating Procedure for Informed Consent Process Execution in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/054/2025
Supersedes SOP/BA-BE/054/2022
Page No. Page 1 of 11
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To outline the procedure for obtaining and documenting informed consent from healthy volunteers prior to participation in any Bioavailability/Bioequivalence (BA/BE) study-related procedures, in accordance with ICH-GCP, Schedule Y, and ethical standards.

2. Scope

This SOP applies to all clinical staff involved in conducting the informed consent process in BA/BE studies at the clinical site, including pre-screening, screening, and study enrolment phases.

3. Responsibilities

  • Investigator/Sub-Investigator: Explains study details to the volunteer and answers all questions.
  • Clinical Research Coordinator: Assists in organizing the consent session, ensures correct version of ICF is used, and witnesses the consent process.
  • Quality Assurance: Verifies that consent documents are complete, accurate, and archived.
See also  BA-BE Studies: SOP for Regulatory Submission Planning for BE Studies - V 2.0

4. Accountability

The Principal Investigator is accountable for ensuring that no study-related procedures begin before valid informed consent is obtained and documented.

5. Procedure

5.1 Preparation for Consent Process

  1. Use only Ethics Committee (EC)-approved and current version of the Informed Consent Form (ICF).
  2. Ensure ICF is available in both English and vernacular languages understood by the volunteer.
  3. Arrange a quiet and private area for the discussion.

5.2 Conduct of Consent Discussion

  1. Investigator/Sub-Investigator explains the study objective, procedures, risks, benefits, compensation, and the right to withdraw at any time.
  2. Use Annexure-1: Informed Consent Checklist to ensure all elements are covered.
  3. Encourage the volunteer to ask questions and provide adequate time to decide.

5.3 Obtaining and Documenting Consent

  1. After volunteer agrees, obtain signature/thumb impression on the ICF along with date and time.
  2. Ensure the signature of an impartial witness is obtained for illiterate volunteers.
  3. Provide a copy of the signed ICF to the volunteer.
  4. Document the entire process in Annexure-2: Informed Consent Documentation Form.
See also  BA-BE Studies: SOP for Trial Registration with EudraCT - V 2.0

5.4 Special Considerations

  1. For AV consent (if applicable), ensure proper camera angle, identity confirmation, and clear audio-video recording.
  2. Store the AV file securely with restricted access.

5.5 Post-Consent Actions

  1. File the original signed ICF in the subject’s screening folder.
  2. Update the Informed Consent Log (Annexure-3) for each subject enrolled.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • ICF: Informed Consent Form
  • EC: Ethics Committee
  • PI: Principal Investigator
  • AV: Audio-Visual

7. Documents

  1. Informed Consent Checklist – Annexure-1
  2. Informed Consent Documentation Form – Annexure-2
  3. Informed Consent Log – Annexure-3

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules, India
  • CDSCO Guidelines for Audio-Visual Consent
See also  BA-BE Studies: SOP for Handling Confidentiality Agreements with Study Sites - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Informed Consent Checklist

Item Explained (Yes/No) Remarks
Study Purpose Yes Explained in Hindi
Risk and Benefits Yes Volunteer acknowledged

Annexure-2: Informed Consent Documentation Form

Subject ID Date Investigator Witness Name Copy Given
VOL-054 16/04/2025 Dr. Arvind Shah Rahul Patil Yes

Annexure-3: Informed Consent Log

Subject ID ICF Version Date Signed Investigator Remarks
VOL-054 v1.1 16/04/2025 Dr. Arvind Shah Consent completed

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial version Implementation QA Head
17/04/2025 2.0 Added AV consent process and annexures Compliance with CDSCO requirements QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: SOP for Handling and Storing Raw Materials With Biohazard Risks – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version